Showing 2,541 - 2,560 results of 14,967 for search '(( significant increase decrease ) OR ( significant ((degs decrease) OR (we decrease)) ))', query time: 0.55s Refine Results
  1. 2541
  2. 2542
  3. 2543
  4. 2544
  5. 2545
  6. 2546
  7. 2547
  8. 2548
  9. 2549
  10. 2550
  11. 2551

    Supplementary Material for: Significant Dry Weight Reduction After Transition from Peritoneal Dialysis to Hemodialysis by Lin Y.-T. (17065287)

    Published 2025
    “…Echocardiographic parameters showed no significant changes. However, serum albumin and hemoglobin levels increased slightly but significantly after the transition, and the number of antihypertensive medications was also reduced. …”
  12. 2552

    Isotype control overlays. by Chen Lu (135200)

    Published 2025
    “…In bone marrow derived mesenchymal stem cells treated rats, the morbidity and mortality of decompression markedly decreased. The increases of protein IL-1 and IL-6 in BALF and lung wet/dry ratio and lung injury score were alleviated. …”
  13. 2553

    Original uncropped blot. by Chen Lu (135200)

    Published 2025
    “…In bone marrow derived mesenchymal stem cells treated rats, the morbidity and mortality of decompression markedly decreased. The increases of protein IL-1 and IL-6 in BALF and lung wet/dry ratio and lung injury score were alleviated. …”
  14. 2554

    Raw Data. by Chen Lu (135200)

    Published 2025
    “…In bone marrow derived mesenchymal stem cells treated rats, the morbidity and mortality of decompression markedly decreased. The increases of protein IL-1 and IL-6 in BALF and lung wet/dry ratio and lung injury score were alleviated. …”
  15. 2555

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  16. 2556

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  17. 2557

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…Postmenopausal osteoporosis (PMO) is characterized by an imbalance in bone remodeling with increased osteoclast and decreased osteoblast activity, leading to bone loss and higher fracture risk. …”
  18. 2558
  19. 2559
  20. 2560